2. Signaling Pathways
  3. Cytoskeleton
  4. Collagen

Collagen

Collagen

Collagens are the most abundant proteins in mammals. The collagen family comprises 28 members that contain at least one triple-helical domain. Beyond the existence of 28 collagen types, further diversity occurs in the collagen family because of the existence of several molecular isoforms for the same collagen type (e.g., collagens IV and VI) and of hybrid isoforms comprised of a chains belonging to two different collagen types (type V/XI molecules). Collagens are deposited in the extracellular matrix where most of them form supramolecular assemblies. Four collagens are type II membrane proteins that also exist in a soluble form released from the cell surface by shedding. Collagens play structural roles and contribute to mechanical properties, organization, and shape of tissues. They interact with cells via several receptor families and regulate their proliferation, migration, and differentiation[1].

Collagen Related Products (74):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-126734
    Avenanthramide E
    		Inhibitor
    Avenanthramide E (Compound 5) is a collagen synthesis inhibitor. Avenanthramide E inhibits TGF-β-stimulated Collagen synthesis. Avenanthramide E can be used for the research of diabetic nephropathy.
    Avenanthramide E
  • HY-P5081
    Endotrophin (Mus musculus)
    Endotrophin (Mus musculus) is an adipokine, a cleavage fragment derived from Collagen VI, whose levels are elevated in adipose tissue and breast tumors of obese mice. Endotrophin (Mus musculus) activates the TGF-β signaling pathway and reduces the expression of hormone-sensitive lipase. Endotrophin (Mus musculus) induces adipogenesis, lipid accumulation, fibrosis, inflammation, angiogenesis, adipose tissue expansion, epithelial-mesenchymal transition, and insulin resistance; it also induces Cisplatin (HY-17394) resistance in cancer cells. Endotrophin (Mus musculus) can be used in research related to metabolic diseases such as obesity and type 2 diabetes, as well as cancers such as breast cancer.
    Endotrophin (Mus musculus)
  • HY-P11826
    T2 peptide-1
    		Inhibitor
    T2 peptide-1 is a linear peptide derived from Lumican degradation. T2 peptide-1 exhibits activity against endometrial adhesion progression and ability to inhibit the Lumican−Collagen I interaction. T2 peptide-1 can be used for the research of liver fibrosis.
    T2 peptide-1
  • HY-181993
    JNK3-IN-11
    JNK3-IN-11 is a selective JNK3 inhibitor with an IC50 of 2.08 nM. JNK3-IN-11 binds to the JNK3 ATP-binding pocket, forming conserved hydrogen bonds with Met149 and a water-mediated hydrogen bond with Lys93. JNK3-IN-11 suppresses TGF-β1-induced c-Jun phosphorylation, reduces profibrotic markers COL1A1 and PAI-1, restores E-cadherin expression, and has protection against podocyte injure. JNK3-IN-11 can be used for the research of chronic kidney disease.
    JNK3-IN-11
  • HY-179645
    Phosphodiesterase-IN-5
    		Inhibitor
    Phosphodiesterase-IN-5 is a potent, orally active and selective phosphodiesterase 10A (PDE10A) inhibitor with an IC50 of 6.2 nM. Phosphodiesterase-IN-5 shows >1612-fold selectivity over other PDEs. Phosphodiesterase-IN-5 exhibits potent antifibrotic efficacy in a Bleomycin (BLM) (HY-108345)-induced murine model of pulmonary fibrosis (PF) by blocking myofibroblast differentiation via the cAMP/PKA/CREB signaling pathway. Phosphodiesterase-IN-5 can be used for the research of PF.
    Phosphodiesterase-IN-5
  • HY-181808
    HSF1/AMPK activator 1
    		Inhibitor
    HSF1/AMPK activator 1 is a compound that modulates the HSF1/AMPK axis and the TGF-β1/Smad signaling pathway. HSF1/AMPK activator 1 exhibits anti-hepatic fibrosis activity and metabolic stability. HSF1/AMPK activator 1 inhibits fibrosis formation and cell proliferation in activated hepatic stellate cells. HSF1/AMPK activator 1 alleviates liver injury and hepatic fibrosis symptoms in fibrotic mice. HSF1/AMPK activator 1 is applicable to research related to hepatic fibrosis.
    HSF1/AMPK activator 1
  • HY-182904
    GV-001
    		Inhibitor
    GV-001 is a selective and orally active HDAC6 inhibitor with an IC50 of 1.18 nM against HDAC6. GV-001 selectively enhances α-tubulin acetylation, reduces sIL-6 and Collagen I levels, suppresses renal cyst growth, and upregulates PC1 expression. GV-001 can be used for the study of autosomal dominant polycystic kidney disease (ADPKD).
    GV-001
  • HY-14239
    Rebimastat
    Rebimastat (BMS 275291) is an orally active, broad-spectrum MMP inhibitor and non-peptide collagen mimetic. Rebimastat has some selectivity because it does not inhibit all MMP activities. Rebimastat can be used in the research of colorectal cancer.
    Rebimastat
  • HY-P992166
    AB-004
    		Ligand
    AB-004 is a humanized monoclonal antibody and ADC targeting uPARAP. AB-004 can be conjugated with the topoisomerase-1 inhibitor P1021 via a protease-cleavable tetrapeptide linker to form the ADC ADCE-D01. AB-004 binds to tumor cells expressing uPARAP, triggering the endocytosis of the ADC. AB-004 is applicable for cancer research.
    AB-004
  • HY-N17906
    Bletimalate C
    		Inhibitor
    Bletimalate C is a 2-isobutyl malate ester present in the tubers of Bletilla striata. Bletimalate C potently inhibits the production of total Collagen in TGF-β1-activated NIH/3T3 cells, with an IC50 of 22.16 μM. Bletimalate C can be used for the research of pulmonary fibrosis.
    Bletimalate C
  • HY-123958
    SB772077B
    		Inhibitor
    SB772077B is a ROCK inhibitor. SB772077B has an anti-inflammatory activity and enhances aqueous outflow facility (OF) by inactivating RhoA/ROCK signal pathway. SB772077B significantly reduces the mRNA level of β-catenin and protein level of fibrotic markers, such as vinculin, fibronectin, collagen 1 A and vimentin. SB772077B also has vasodialatory activity and decreases pulmonary and systemic blood pressure. SB772077B can be used for glaucoma research and pulmonary hypertensive disorder research.
    SB772077B
  • HY-P10739C
    WYRGRLC
    		Inhibitor
    WYRGRLC is a type II collagen-targeting peptide. WYRGRLC specifically binds to type II collagen α1 in articular cartilage in a sequence-dependent manner. WYRGRLC inhibits the binding of WYRGRL-displaying phage (C1-3) to articular cartilage in a sequence-specific manner. WYRGRLC can act as a retention enhancer to improve the cartilage-targeting ability of polymeric nanoparticles and liposomal nanoplatforms, facilitating the delivery of Rapamycin (HY-10219) to chondrocytes. WYRGRLC can be used in studies related to osteoarthritis.
    WYRGRLC
  • HY-W746556
    Methyl cholate-d5
    		Inhibitor
    Methyl cholate-d5 is the deuterium labeled Methyl cholate. Methyl cholate is a bile acid analog and a specific inhibitor of TcdB toxin from Clostridioides difficile. Methyl cholate exerts a stronger selective inhibitory effect on TcdB than on TcdA. Methyl cholate induces conformational stabilization by binding to a unique site of TcdB, thereby blocking the binding of the toxin to host receptors and its self-processing process. Methyl cholate effectively protects human fibroblasts from TcdB-induced cytopathic effects. Methyl cholate exhibits dose-dependent anti-hepatic fibrosis activity in both cellular and zebrafish models, and significantly reduces the expression levels of α-SMA and COL-I. Methyl cholate is suitable for in-depth research in the fields of Clostridioides difficile infection and hepatic fibrosis.
    Methyl cholate-d<sub>5</sub>
  • HY-182038
    TGF-β1/Smad3-IN-2
    TGF-β1/Smad3-IN-2 is an orally active antifibrotic agent. TGF-β1/Smad3-IN-2 has high affinity for VDR and can inhibit the TGFβ/SMAD3 signaling pathway. TGF-β1/Smad3-IN-2 inhibits hepatic stellate cell activation, reduces extracellular matrix deposition, and alleviates liver fibrosis in a bile duct ligation mouse model. TGF-β1/Smad3-IN-2 can be used for the research of liver fibrosis.
    TGF-β1/Smad3-IN-2
  • HY-P11087
    P15
    P15 is a collagen mimetic peptide with the sequence of GTPGPQGIAGQRGVV. P15 can mimic the cell-binding domain of human type I collagen. P15 is capable of promoting the adhesion, proliferation, and differentiation of osteoblasts. Biomaterials modified with P15 can be used in research related to bone regeneration.
    P15
  • HY-180336
    LM9
    		Inhibitor
    LM9 is a potent, orally active MyD88 inhibitor. LM9 blocks TLR4/MyD88 binding, MyD88 homodimer formation, and TLR4/MyD88/NF-κB signaling pathway activation. LM9 prevents atherosclerosis by regulating inflammatory responses and oxidative stress in macrophages. LM9 efficiently mitigates inflammatory responses and fibrosis in obesity-induced cardiomyopathy. LM9 can be used for fibrosis and atherosclerosis research.
    LM9
  • HY-180585
    LOXL2/sGC modulator-2
    		Inhibitor
    LOXL2/sGC modulator-2 (Compound 9k) is a selective and orally active lysyl oxidase-like 2 (LOXL2) and soluble guanylate cyclase (sGC) dual-target regulator. LOXL2/sGC modulator-2 shows inhibitory activity for LOXL2 with an IC50 of 0.1 μM and can activate sGC. LOXL2/sGC modulator-2 can ameliorate vascular remodeling and reduce pulmonary artery pressure. LOXL2/sGC modulator-2 can downregulate PKG1, PCNA, α-SMA, collagen I and fibronectin levels. LOXL2/sGC modulator-2 can be used for the research of pulmonary arterial hypertension .
    LOXL2/sGC modulator-2
  • HY-W014075R
    1-Hydroxypyrene (Standard)
    		Activator
    1-Hydroxypyrene (Standard) is the analytical standard of 1-Hydroxypyrene (HY-W014075). This product is intended for research and analytical applications. 1-Hydroxypyrene, a biomarker of exposure to polycyclic aromatic hydrocarbons (PAHs), is analyzed in urine samples. 1-Hydroxypyrene is the major biomarker of exposure to pyrenes. 1-Hydroxypyrene is the orally active agonist for aryl hydrocarbon receptor (AhR) and can lead to renal fibrosis.
    1-Hydroxypyrene (Standard)
  • HY-P11794
    Type IV collagen peptide
    Type IV collagen peptide is a cell-binding ligand peptide derived from type IV collagen. (The sequence is TAGSCLRKFSTM).
    Type IV collagen peptide
  • HY-177739
    Antifibrotic agent 2
    		Inhibitor
    Antifibrotic agent 2 (Compound 636) is a polycyclic pyridinone derivative with antifibrotic activity. Antifibrotic agent 2 reduces the pathological accumulation of fibrosis-related proteins such as fibronectin and collagen, prevents excessive fibrous connective tissue from depositing in organs or tissues, and reverses or delays the remodeling of tissue fibrosisby regulating the abnormal proliferation and activation of fibroblasts. Antifibrotic agent 2 can be used for research on pulmonary fibrosis.
    Antifibrotic agent 2